Korro Bio, Inc.: stock overview

KRRONASDAQHealthcare · Pharmaceutical Preparations

Price

$12.18

November 20, 2026Market cap $218M

What Ploutos Investor adds for Korro Bio

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Korro Bio had revenue of $1.3M over the last 12 months and a net loss of $106M. Revenue fell by 29.6% a year on average over the last 5 years. It holds more cash than debt, by $105M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.

Its SEC filings
Market cap
$218M
17.87M shares
P/E
–
Revenue, 12 months
$1.3M
-29.6% a year over 5 years
Net margin
-8,214.5%

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

Fiscal years in figures

KRRO's revenue, profit, cash flow and dividend with each year-end price, from 2019 to 2022, 4 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $357M
$218M
Enterprise value 
$113M
P/E 
–
EV / EBIT 
–
EV / Revenue 
87.2
P/B 3-year median: 2.2
2.5
FCF yield 3-year median: -21.8%
–
Earnings yield 3-year median: -110.7%
–

Profitability

Operating margin 
-8,467.3%
Net margin 
-8,214.5%
ROIC 
-93.6%
ROIC, 5-year average 
-90.6%
ROE 
-114.9%

Growth

Revenue, yearly change 
+181.5%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
-29.6%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$105M
Total debt 
$42M
Of which operating leases 
$42M
Net cash 
$105M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
7.30

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+0.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Korro Bio, Inc.
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
17.87M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Korro Bio's filings show?

These are Korro Bio's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about KRRO

Didn't find what you were looking for?

Ask us
What is KRRO's market cap?

Korro Bio, Inc.'s market cap is $218M, at a price of $12.18 on November 20, 2026 and 17.87M shares.

How much revenue does KRRO have?

Korro Bio had revenue of $1.3M over the last 12 months. Over the last 5 years it changed by -29.6% a year on average.

Does KRRO pay a dividend?

No. Korro Bio paid no regular dividend over the last 12 months.

Where do the figures come from?

From Korro Bio, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.